Name: RGD peptide (Arg-Gly-Asp)
Brand: Selleck Chemicals
SKU: S8008
Availability: InStock
Rating: 5 (27 reviews)

Jump to

Quality Control

Batch: Purity: 98.8%

98.8

Related Targets	Akt Wnt/beta-catenin PKC HSP ROCK Microtubule Associated Bcr-Abl Actin FAK Kinesin
Other Integrin Inhibitors	SB273005 Cilengitide trifluoroacetate Cilengitide (EMD 121974) ATN-161 Cyclo(RGDyK) TFA Cyclo(-RGDfK) TFA Leukadherin-1 A-205804 RGD peptide (GRGDNP) Pyrintegrin

Solubility

In vitro
Batch:

Water : 22 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	346.34	Formula	C₁₂H₂₂N₆O₆	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	99896-85-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	C(CC(C(=O)NCC(=O)NC(CC(=O)O)C(=O)O)N)CN=C(N)N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Integrin
In vitro	The RGD sequence is the cell attachment site of a large number of adhesive extracellular matrix, blood, and cell surface proteins, and nearly half of the over 20 known integrins recognize this sequence in their adhesion protein ligands. The RGD peptides and mimics can be used to probe integrin functions in various biological systems. Drug design based on the RGD structure may provide new treatments for diseases such as thrombosis, osteoporosis, and cancer. RGD peptide acts as an inhibitor of integrin-ligand interactions and can induce apoptosis in the absence of signals and integrin-mediated cell clustering. Research demonstrates that RGD peptides promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. The RGD peptide can serve as a cell adhesion site of extracellular matrix, cell surface proteins, and integrins. In addition, RGD peptide can inhibit ACK-2 activation through cell adhesion.
References	[1] https://pubmed.ncbi.nlm.nih.gov/8970741/ [2] https://pubmed.ncbi.nlm.nih.gov/10028971/ [3] https://pubmed.ncbi.nlm.nih.gov/17708932/ [4] https://pubmed.ncbi.nlm.nih.gov/10085085/ [5] https://pubmed.ncbi.nlm.nih.gov/15990462/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06693986	RECRUITING	Adenocarcinoma of Pancreas	Masonic Cancer Center, University of Minnesota	2024-12-27	PHASE1
NCT01608516	TERMINATED	Inflammation; Atheromatous Plaques; Carotid Artery Diseases	University of Lausanne Hospitals	2012-04	PHASE1; PHASE2
NCT05549024	RECRUITING	Breast Cancer; Prostate Cancer; Brain Tumor; PET/CT Imaging	Peking Union Medical College Hospital	2022-08-16	EARLY_PHASE1
NCT05543954	UNKNOWN	Lung Neoplasms	Peking Union Medical College Hospital	2022-09-03	EARLY_PHASE1
NCT06632860	RECRUITING	Iodine-resistant Thyroid Cancer; Meningioma; NETs	Peking Union Medical College Hospital	2024-08-01	EARLY_PHASE1
NCT03505346	UNKNOWN	Chronic Ischemic Heart Disease	Rigshospitalet, Denmark	2024-01-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

RGD peptide (Arg-Gly-Asp) Tripeptide

Chemical Structure

Molecular Weight: 346.34